CLCN7 Gene

CLCN7 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CLCN7 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CLCN7</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Chloride Voltage-Gated Channel 7</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>16p13.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1191</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>602727</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000132449</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P51797</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[Osteopetrosis](/diseases/osteopetrosis), [Alzheimer Disease](/diseases/alzheimers-disease), [Parkinson Disease](/diseases/parkinsons-disease)</td>
</tr>
</table>

CLCN7 (Chloride Voltage-Gated Channel 7) encodes ClC-7, a late endosomal and lysosomal chloride channel critical for bone resorption and lysosomal function. Mutations in this gene cause severe bone disorders including autosomal dominant osteopetrosis type II (ADO2) and are increasingly recognized in neurodegenerative diseases [@kornak2001].

CLCN7 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CLCN7 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CLCN7</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Chloride Voltage-Gated Channel 7</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>16p13.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1191</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>602727</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000132449</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P51797</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[Osteopetrosis](/diseases/osteopetrosis), [Alzheimer Disease](/diseases/alzheimers-disease), [Parkinson Disease](/diseases/parkinsons-disease)</td>
</tr>
</table>

CLCN7 (Chloride Voltage-Gated Channel 7) encodes ClC-7, a late endosomal and lysosomal chloride channel critical for bone resorption and lysosomal function. Mutations in this gene cause severe bone disorders including autosomal dominant osteopetrosis type II (ADO2) and are increasingly recognized in neurodegenerative diseases [@kornak2001].

The CLCN7 gene is a member of the CLC chloride channel family, which comprises both plasma membrane channels and intracellular voltage-gated chloride channels. ClC-7 functions as a homodimeric channel that conducts chloride ions across the lysosomal membrane, working in concert with the V-ATPase to enable proper lysosomal acidification and function [@zifarelli2008].

Overview

The CLCN7 gene encodes a protein essential for lysosomal and endosomal function. Its role in neurodegenerative diseases is being increasingly recognized, with evidence linking CLCN7 dysfunction to impaired autophagic degradation—a key mechanism in both [Alzheimer disease](/diseases/alzheimers-disease) and [Parkinson disease](/diseases/parkinsons-disease) [@jentsch2015].

Dysregulation or mutations in CLCN7 contribute to the pathogenesis of neurodegenerative disorders through impaired lysosomal function, leading to accumulation of toxic protein aggregates and neuronal dysfunction [@wen2022].

Basic Information

Protein Structure and Function

Molecular Architecture

ClC-7 is a 805-amino acid protein that forms homodimers in the lysosomal membrane. Each subunit contains 18 transmembrane domains and functions as an independent channel pore. The protein has two important regulatory domains:

Tissue Distribution

• Bone: Osteoclasts — highly expressed, critical for bone resorption
• Brain: [Neurons](/entities/neurons), particularly in [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), and [substantia nigra](/brain-regions/substantia-nigra)
• Kidney: Tubular cells
• Liver: Hepatocytes

Physiological Roles

Role in Neurodegeneration

Alzheimer Disease

Recent research has identified a potential link between CLCN7 and [Alzheimer disease](/diseases/alzheimers-disease). The lysosomal chloride channel activity is essential for proper clearance of amyloid-beta peptides through the autophagic-lysosomal pathway [@huber2019]. Impaired CLCN7 function may contribute to:

• Reduced clearance of amyloid-beta plaques
• Impaired tau protein degradation
• Dysregulated lysosomal function in [microglia](/entities/microglia)

Parkinson Disease

In [Parkinson disease](/diseases/parkinsons-disease), CLCN7 dysfunction may impair mitophagy and lysosomal clearance of alpha-synuclein aggregates [@wen2022]. The substantia nigra is particularly vulnerable due to its high lysosomal activity.

Lysosomal Storage Disorders

CLCN7 mutations cause autosomal dominant osteopetrosis characterized by abnormally dense bone formation. Interestingly, some patients with CLCN7 mutations also exhibit neurodegeneration, suggesting a shared mechanism with lysosomal storage disorders [@weinert2010].

Molecular Pathways

Disease Associations

Autosomal Dominant Osteopetrosis (ADO2)

• Mutations: Heterozygous missense mutations (gain-of-function)
• Features: Increased bone density, fractures, cranial nerve compression
• Inheritance: Autosomal dominant
• Onset: Adulthood

Autosomal Recessive Osteopetrosis (ARO)

• Mutations: Homozygous loss-of-function mutations
• Features: Severe skeletal sclerosis, bone marrow failure, early death
• Inheritance: Autosomal recessive

Neurodegeneration

• Mechanism: Impaired lysosomal function due to channel dysfunction
• Phenotype: Progressive neurological deterioration in some patients
• Associated proteins: [PINK1](/entities/pink1-protein), [Parkin](/entities/parkin-protein), [GBA](/entities/gba)

Therapeutic Implications

Small Molecule Activators

• CLCN7 agonists: Being explored to enhance lysosomal function
• V-ATPase modulators: May compensate for CLCN7 dysfunction

Gene Therapy

• AAV-CLCN7: Being developed for autosomal recessive osteopetrosis
• CRISPR approaches: Potential for correcting specific mutations

Drug Targets

Animal Models and Research

Mouse Models

CLCN7 knockout mice recapitulate the human osteopetrosis phenotype, exhibiting severe bone sclerosis and reduced bone marrow cavity. These models have been instrumental in understanding the channel's role in both skeletal and neuronal biology. Interestingly, some CLCN7-deficient mouse models show age-dependent neurodegeneration, providing direct evidence for the channel's importance in neuronal health [@kornak2001].

Cellular Models

• Clcn7-knockout fibroblasts: Show impaired lysosomal acidification and reduced autophagic flux
• Osteoclast cultures: Demonstrate critical role in bone resorption via defective acidification
• Neuronal cultures: Exhibit accumulation of autophagic vesicles and reduced protein clearance

Clinical Significance

Diagnostic Considerations

• Genetic testing: Available for CLCN7 mutations in clinical laboratories
• Biochemical markers: Elevated lysosomal enzymes in patient serum
• Imaging: CT scans reveal characteristic bone sclerosis pattern

Patient Management

• Bone biopsies: Show characteristic osteosclerotic changes
• Neurological evaluation: Recommended for patients with CLCN7 variants
• Multidisciplinary care: Involves geneticists, neurologists, and orthopedic surgeons

Family Screening

• Autosomal dominant inheritance: 50% risk to offspring
• Prenatal testing: Available for at-risk pregnancies
• Carrier detection: Molecular testing for family members

Research Gaps and Future Directions

Key Publications

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=CLCN7) - Biomedical literature
• [OMIM](https://www.omim.org/entry/602727) - Online Mendelian Inheritance in Man
• [UniProt](https://www.uniprot.org/uniprot/P51797) - Protein database
• [Allen Brain Atlas](https://human.brain-map.org/) - Brain gene expression data

Pathway Diagram

The following diagram shows the key molecular relationships involving CLCN7 Gene discovered through SciDEX knowledge graph analysis: